Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Mar;31(2):103-12.
doi: 10.1002/hup.2517. Epub 2016 Feb 8.

The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial

Negar Iranpour  1 , Atefeh Zandifar  1 , Mehdi Farokhnia  1 , Amirhossein Goguol  1 , Habibeh Yekehtaz  1 , Mohammad-Reza Khodaie-Ardakani  2 , Bahman Salehi  3 , Sophia Esalatmanesh  1 , Atefeh Zeionoddini  1 , Payam Mohammadinejad  1 , Arefeh Zeinoddini  1 , Shahin Akhondzadeh  1
Affiliations
Randomized Controlled Trial

The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial

Negar Iranpour et al. Hum Psychopharmacol. 2016 Mar.

Abstract

Objective: The evident central role of inflammation, oxidative stress, and metabolic derangement in pathophysiology of negative symptoms of schizophrenia has opened new insights into probable pharmacological options for these symptoms. Pioglitazone is an antidiabetic agent with anti-inflammatory and antioxidant properties. In this study, we evaluated the efficacy of pioglitazone as an adjunct to risperidone for reduction of negative symptoms in schizophrenia.

Methods: In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks. Patients' symptoms and adverse events were rated at baseline and weeks 2, 4, 6, and 8. The difference between the two groups in decline of PANSS negative subscale scores was considered as the primary outcome of this study.

Results: At the study endpoint, patients in the pioglitazone group showed significantly more improvement in PANSS negative subscale scores (p < 0.001) as well as PANSS total scores (p = 0.01) compared with the placebo group.

Conclusion: These findings suggest the probable efficacy of pioglitazone as an augmentation therapy in reducing the negative symptoms of schizophrenia.

Keywords: clinical trial; negative symptoms; pioglitazone; schizophrenia; thiazolidinedione.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

None to declare

Figures

Figure 1.
Figure 1.
Flow diagram of the study
Figure 2.
Figure 2.
Comparison of Positive and Negative Syndrome Scale (PANSS) negative subscale scores (A), PANSS positive subscale scores (B), PANSS general psychopathology subscale scores (C), and PANSS total scores (D) between two groups over time (*p-value < 0.05, **p-value < 0.001); p-value represents the results of independent sample T-tests
See this image and copyright information in PMC

References

    1. Abbasi SH, Mohammadinejad P, Shahmansouri N, et al. 2015. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. J Affect Disord 183: 149–155. - PubMed
    1. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. 2007. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90(1–3): 179–185. - PubMed
    1. Al-Asmari A, Khan MW. 2014. Inflammation and schizophrenia: alterations in cytokine levels and perturbation in antioxidative defense systems. Hum Exp Toxicol 33(2): 115–122. - PubMed
    1. Benedusi V, Martorana F, Brambilla L, Maggi A, Rossi D. 2012. The peroxisome proliferator-activated receptor gamma (PPARgamma) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis. J Biol Chem 287(43): 35899–35911. - PMC - PubMed
    1. Brasier AR. 2006. The NF-kappaB regulatory network. Cardiovasc Toxicol 6(2): 111–130. - PubMed

Publication types

LinkOut - more resources